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 Abstract 
 Long QT syndrome (LQTS) is a genetic cardiac condition associated with prolonged ventricular repolarization, primarily 
a result of perturbations in cardiac ion channels, which predisposes individuals to life-threatening arrhythmias. Using DNA 
screening and sequencing methods, over 700 different LQTS-causing mutations have been identifi ed in 13 genes worldwide. 
Despite this, the genetic cause of 30 – 50% of LQTS is presently unknown. MicroRNAs (miRNAs) are small ( ~ 22 nucle-
otides) noncoding RNAs which post-transcriptionally regulate gene expression by binding complementary sequences within 
messenger RNAs (mRNAs). The human genome encodes over 1800 miRNAs, which target about 60% of human genes. 
Consequently, miRNAs are likely to regulate many complex processes in the body, indeed aberrant expression of various 
miRNA species has been implicated in numerous disease states, including cardiovascular diseases. MiR-1 and MiR-133A 
are the most abundant miRNAs in the heart and have both been reported to regulate cardiac ion channels. We hypothesized 
that, as a consequence of their role in regulating cardiac ion channels, genetic variation in the genes which encode MiR-1 
and MiR-133A might explain some cases of LQTS. Four miRNA genes ( miR-1-1 ,  miR-1-2 ,  miR-133a-1 and  miR-133a-2 ), 
which encode MiR-1 and MiR-133A, were sequenced in 125 LQTS probands. No genetic variants were identifi ed in  miR-
1-1 or  miR-133a-1 ; but in miR-1-2 we identifi ed a single substitution ( n.100A  G ) and in  miR-133a-2 we identifi ed two 
substitutions ( n.  19G  A and  n.98C  T ). None of the variants affect the mature miRNA products. Our fi ndings indicate 
that sequence variants of  miR-1-1 ,  miR-1-2 ,  miR-133a-1 and  miR-133a-2 are not a cause of LQTS in this cohort. 
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 Background 
 Long QT syndrome (LQTS) is a genetic condition 
characterized by prolongation of the QT interval, 
syncopal attacks, T-wave abnormalities, ventricular 
tachycardia of the torsades de pointes (TdP) type 
and an increased risk of sudden death [1]. 
 The population prevalence of LQTS is esti-
mated to be between 1:2000 and 1:5000 [1,2] 
and the disease phenotype is associated with highly 
variable expressivity [3] and incomplete penetrance 
[4]. Presently, using genetic screening and DNA 
sequencing techniques, over 700 LQTS-causing 
mutations have been identifi ed in 13 genes [5,6]. 
These genes are involved in the correct execution 
of the cardiac action potential. Genetic screening 
of the fi ve most frequently affected genes ( KCNQ1 , 
 KCNH2 ,  SCN5A ,  KCNE1 and  KCNE2 ) results in 
the identifi cation of a disease-causing mutation in 
50 – 70% of symptomatic LQTS cases [7]; the addi-
tional eight genes, which complete the list of 
LQTS-causative genes known presently, each 
account for very few LQTS cases [5,6]. A number 
of LQTS cases, with as-yet-unknown genetic aeti-
ology, might be attributable to mutations in genes 
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which regulate the expression of these LQTS-
causing genes. 
 Initially characterized by Lee et  al. [8] in 1993, 
microRNAs (miRNA) are  fi rst transcribed as long pri-
miRNA transcripts containing a stem loop secondary 
structure, which, when excised by splicing or cleaved 
by the nuclear RNA cleaving enzyme, Drosher, is 
called pre-miRNA. Removal of the terminal loop from 
the pre-miRNA by the cytoplasmic RNA cleaving 
enzyme, Dicer, produces the small ( ~ 22 nucleotides) 
mature miRNA duplex [9]. Usually, one strand is 
preferentially selected for entry into the RNA-induced 
silencing complex (RISC), while the other strand, 
known as the miRNA * strand, is degraded. RISC is a 
multi-protein complex which uses the single stranded 
miRNA as a template for recognizing complementary 
messenger RNAs (mRNAs). The targeted transcripts 
are regulated through the binding of these comple-
mentary sequences and subsequent repression of gene 
expression through the regulation of mRNA transla-
tion or degradation [8,10 – 12]. The miRNAs of ani-
mals achieve this regulation through an imperfect 
association with mRNA target regions [13 – 15]. Fur-
thermore, this incomplete complementarity with tar-
gets provides an opportunity for animal miRNA ’ s to 
bind multiple different mRNA targets; similarly a 
given target might bind multiple miRNAs [16,17]. 
 The human genome may encode over 1800 miR-
NAs [18,19], which target about 60% of human 
genes [13,20]. Consequently, miRNAs are likely to 
be involved in most biological processes [14,21]. 
Indeed, miRNAs have been reported to regulate 
many complex processes in the body and aberrant 
expression of various miRNA species has been impli-
cated in numerous disease states including cancer 
[22], diabetes [23,24], systemic lupus erythematosus 
[25] and cardiovascular disease, e.g. heart failure, 
hypertrophy, conduction disturbances and arrhyth-
mogenesis [26 – 35]. 
 MiR-1 and MiR-133A are muscle-specifi c miR-
NAs, expressed predominantly in the heart and skel-
etal muscle [36]; they are the most abundant miRNAs 
expressed in the heart [30,37]. The bicistronic 
miRNA clusters encoding  miR-133a-1 / miR-1-2 
(located on chromosome 18) and  miR133a-2 / miR-
1-1 (located on chromosome 20) are regulated coop-
eratively by the myocyte enhancer factor-2 (MEF2) 
transcription factor and the serum response factor 
(SRF) which are essential regulators of muscle devel-
opment [38,39]. The sequences of the mature  miR-
1-1 and  miR1-2 are identical (MiR-1), as are those 
of  miR-133a-1 and  miR-133a-2 (MiR-133A). Targets 
of MiR-1 and MiR-133A include those mRNA tran-
scripts encoding proteins involved in cardiovascular 
development [29], hypertrophy [26,27] and ion 
channel function [30]. Ion channels, such as  RYR2 , 
 KCNQ1 and  KCND2 , have been shown to be regu-
lated, at least in part, by MiR-1 or MiR-133A 
[34,35,40]. 
 MiR-1 was shown to play a role in cardiac mor-
phogenesis and conduction in a genetic knockout 
mouse model [35]. Mice lacking miR-1-2 show an 
approximate 50% lethality between late embryogen-
esis and shortly after birth, as a consequence of ven-
tricular septal defects. Postnatal survivors displayed a 
range of cardiac phenotypes, however while most 
 displayed no structural dysfunction many suffered 
sudden death. Electrocardiography of mutant mice 
showed that many mutant carriers displayed pro-
longed ventricular depolarisation [35]. Mice lacking 
either MiR-133A gene did not exhibit cardiac defects 
nor was their life span reduced compared to control 
animals [41]. However, increased levels of MiR-
133A prolong the action potential in isolated ven-
tricular myocytes and cause QT prolongation in 
mice [31]. Furthermore, using a guinea pig model, 
Shan et  al. could show that increasing MiR-1 and 
MiR-133A induced QT prolongation, while anti-
sense silencing of MiR-1 and MiR-133A abolished 
Arsenic trioxyde-induced QT prolongation [42]. 
MiR-133A was shown to bind to the 3 ¢ UTR of 
KCNQ1 mRNA which encodes Kv7.1 [40]. Kv7.1 
is the pore-forming subunit of the voltage-gated 
potassium channel which is responsible for the I Ks 
cardiac potassium current. This current is essential 
for the repolarisation phase of the cardiac action 
potential, and mutations in  KCNQ1 are known to 
cause a loss-of-function phenotype, which manifests 
clinically as LQTS [5]. 
 We hypothesized that genetic variation in MiR-1 
or MiR-133A might explain some cases of LQTS 
as the phenotype is a result of loss-of-function 
and gain-of-function perturbations in cardiac ion 
channels. 
 Methods 
 Patient samples 
 Unrelated probands, referred from specialist cardiol-
ogy centres in Denmark and the UK to Statens 
Serum Institut for genetic investigation of LQTS 
( n    125; 70% female), were included in this retro-
spective study. These probands are primarily of 
Northern European descent (96%) and conse-
quently, data from various European genetics screen-
ing panels (retrieved from NCBI dbSNP) were used 
as  in silico control of allele frequencies. 
 The probands had been screened for mutations 
in  KCNQ1 ,  KCNH2 ,  SCN5A ,  KCNE1 and  KCNE2 
by capillary-electrophoresis single strand conforma-
tion polymorphism (CE-SSCP) followed by DNA 
sequencing of aberrant conformers as described else-
where [43 – 45]. Screening for mutations in  CAV3 was 
previously performed by direct sequencing [46]. 
Forty-eight (38%) had been found to carry a prob-
ably damaging variant in any one of these genes [47], 
these constitute the mutation carrier sub-group. 
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Those probands in whom no mutation was identifi ed 
constitute the non-mutation carrier sub-group. 
 Ethics statement 
 This study was performed in accordance with the 
Helskini Declaration of 1975, as revised in 1983. All 
patients gave informed consent. 
 Genetic screening 
 DNA extraction. Genomic DNA (gDNA) was 
extracted from frozen EDTA-blood using a Qiagen 
kit (Qiagen, QmbH, Hilden, Germany). 
 Polymerase chain reaction. Four miRNA genes ( mir-
1-1 ,  mir-1-2 ,  mir-133a-1  &  mir-133a-2 ) were PCR 
amplifi ed from 125 gDNA samples (Table I). Prim-
ers were designed using NCBI/Primer-BLAST pro-
gram [48] (Table I); all primers were modifi ed with 
M13 tails (F: TGTAAAACGACGGCCAGT; R: 
CAGGAAACAGCTATGACC). 
 A 25  μ L PCR mix incorporated 1 U of TEMPase 
Hot Start DNA Polymerase (Ampliqon ApS), 
1   Tempase buffer I (Ampliqon ApS), 2 mM dNTPs, 
0.4 um of the forward and reverse primers, and 2.5 
ng gDNA template. 
 PCR amplifi cations were performed in GeneAmp  ®  
PCR System 2700 (Applied Biosystems, Foster City, 
CA, USA) using the following amplifi cation proto-
col: initial heat activation step at 95 ° C for 15 min, 
38 cycles of 30 s at denaturing temperature 94 ° C, 45 
s at annealing temperature 58 ° C, and 40 s at exten-
sion temperature 72 ° C, and a fi nal indefi nite hold 
step of 4 ° C. 
 PCR products were quantifi ed by 2% agarose gel 
electrophoresis and product size was confi rmed through 
a visual comparison with Sigma Direct load Wide 
Range DNA marker (Sigma-Aldrich Denmark A/S). 
 Direct sequencing. PCR products were purifi ed 
using ExoSap (Affymetrix, Santa Clara, CA, USA) 
and sequenced using the Big Dye dideoxy terminator 
cycle sequencing kit (Applied Biosystems) and the 
3730 DNA Analyzer (Applied Biosystems). Sequence 
analysis was carried out using the Sequencher 4.9 
software (Gene Codes Corporation, Ann Arbor, 
MI, USA) 
 Data analysis 
 Multiple sequence alignment and nucleotide conservation 
across species. BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) analyses of the two miRNA genes which har-
boured nucleotide variants ( miR-1-2  – NR_029662.1 
and  miR-133a-2  – NR_029676.1) identifi ed several 
similar sequences in a number of species. These 
sequences were aligned in Bioedit using ClustalW in 
order to identify conserved regions [49]. 
 Prediction of RNA secondary structure. RNAfold Web-
server (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
was used to compute the minimum free energy (MFE), 
the partition function, the matrix of base pairing prob-
abilities, and the centroid structure [50]. 
 Statistical analysis 
 Tests for allele frequencies, heterozygosity values, 
genic differentiation and Hardy-Weinberg equilib-
rium were carried out using the exact tests of 
GenePop on the web (http://genepop.curtin.edu.au/). 
Fisher ’ s exact test was used to detect differences in 
allele distribution with respect to mutation status; a 
5% alpha error was considered acceptable. The exact 
Hardy Weinberg test was applied to compare the 
overall frequencies of the identifi ed genotypes and 
verify whether the distribution of these genotypes 
was in Hardy-Weinberg equilibrium [51,52]. 
 Results 
 Three genetic variants were identifi ed in this cohort, 
minor allele frequencies (MAF) for mutation carri-
ers, non-mutation carriers and in silico controls are 
reported in Table II. All variants conformed to Hardy 
Weinberg expectations and there was no statistically 
signifi cant difference in allele frequencies between 
mutation carriers ( n    48) and non-mutation carriers 
( n    77). 
 Table I. Gene information and primer sequences for  mir-1-1, mir-1-2, mir-133a-1 and  mir-133a-2 amplifi cation. 
NCBI ref seq
miRNA 
gene Forward primer Reverse primer Amplicon
NR_029780.1  mir-1-1 
(71 bp)
ACACAGAGAGGGCTCCGGCA ACACGACCGTCCACCAACGC 342 bp
NR_029662.1  mir-1-2 
(85 bp)
TTGCCAAAGGTCATCTGTTCATGACT TGGAACCATTAATGCCATGCTTCAGG 365 bp
NR_029675.1  mir-133a-1 
(88 bp)
AGCGCAGGAAAACAGTAGGA TTTGAAATCCTTAAGTCATCCATACA 444 bp
NR_029676.1  mir-133a-2 
(102 bp)
ATCTCCATCGGGACTGCTT GGGCTTCACTTACTTGGAGCT 264 bp
488 P. L. Hedley et al. 
 No genetic variants were identifi ed in  miR-1-1 ; 
but in  miR-1-2 we identifi ed a single substitution 
(rs9989532:  n.100A  G ) (Figure 1); in nine probands 
(all heterozygote carriers). Multi-species sequence 
comparison of DNA sequences similar to the miR-
1-2 gene region is represented in Figure 2; the  n.100G 
nucleotide is highly conserved among all mammals 
queried as well as zebrafi sh in a region which is highly 
conserved among apes. 
 No sequence variants were detected in  miR-
133a-1 , but in  miR-133a-2 we identifi ed two substi-
tutions ( n.  19G  A and  n.98C  T ) (Figure 1). The 
 n.  19G  A polymorphism occurred in 64 probands 
(eight homozygote carriers and 56 heterozygote car-
riers), while the  n.98C  T variant occurred in a 
single non-mutation carrier, Similar allele frequen-
cies are reported in dbSNP for these variants; 
rs13040413,  n.  19G  A has a reported MAF of 
0.250 in the CEU population and rs200375711, 
 n.98C  T has a reported MAF of 0.002 in the 
ClinSeq population (CSAgilent), a cohort of primar-
ily Caucasian, atherosclerotic heart patients [53] 
(Figure 1, Table II). Multi-species sequence com-
parison of DNA sequences similar to the  miR-133a-2 
gene region is represented in Figure 3; the  n.  19G 
nucleotide is not conserved, however the  n.98C 
nucleotide is highly conserved among all mammals 
queried as well as chicken and zebrafi sh; the region 
surrounding  n.98C is highly conserved among apes. 
 Discussion 
 Presently, mutations in 13 genes are described to cause 
LQTS; taken together mutations in these genes explain 
50 – 70% of LQTS cases. This means that causality in 
30 – 50% of LQTS cases is as yet unknown. Animal 
models suggest that miRNAs might be involved in the 
regulation of cardiac action potential [35]. 
 A number of associations between SNPs in pre-
dicted miRNA binding sites on target mRNAs and 
phenotypic traits have been reported [22,54 – 56]. A 
limitation of this study is that we have not assessed the 
MiR-1 and MiR-133A binding sites of putative target 
transcripts; instead we focused on identifying genetic 
variation within the miRNA genes themselves. 
 SNPs are rarely seen in the seed regions (short 
3 – 8 nucleotide regions important for target specifi c-
ity) of miRNAs; which suggests a strong selective 
constraint on the seed regions of mature miRNA. 
However, Mencia et  al provided the fi rst example of 
 Table II. Minor allele frequencies of the genetic variants identifi ed in this study. 
MAF study 
sub-populations MAF dbSNP populations
Gene SNP ID Variant
LQTSmc 
( n    48)
LQTSnmc 
( n    77)
HapMap-CEU
 ( n    113)
pilot1_CEU_low_
coverage_panel
 ( n    60)
CSAgilent
 ( n    247)
miR-1-2 rs9989532 n.100A   G 0.042 0.032 0.013 0.008
miR-133a-2 rs13040413 n.  19G   A 0.250 0.312 0.250
rs200375711 n.98C   T 0.000 0.006 0.002
 MAF, minor allele frequency; mc, mutation carrier; nmc, non-mutation carrier. All variants were in Hardy Weinberg Equilibrium, allele 
distribution was not signifi cantly different between the two sub-populations. 
 Figure 1. (A) Genomic structure of the miR-1 and miR-133 clusters. (B) Genomic structure of  mir-1-2 and  mir-133a-2 , variants identifi ed 
in this study are represented by a red line. The minor allele frequencies (MAF) indicated here are representative of the CEU population 
as reported in 1000 genomes [60], except rs200375711 ( mir-133a-2:n.98C  T ) which was not identifi ed in 1000 genomes but was identifi ed 
in one of 493 atherosclerosis patients of European descent from the ClinSeq whole-exome sequencing project [53]. This Figure is 
reproduced in colour in the online version of  The Scandinavian Journal of Clinical & Laboratory Investigation . 
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 Figure 2. (A) Pri-miR-1-2 multiple species sequence alignment. Pre-miR-1-2 is indicated in a blue box, mature MiR-1 is indicated in a red 
box, the seed region is highlighted, rs9989532 is indicated by a black arrow. (B) Pre-miR-1-2 secondary structure, mature MiR-1 is indicated 
in red. Secondary structure was predicted using RNAfold Web Server [50]. This Figure is reproduced in colour in the online version of 
The Scandinavian Journal of Clinical & Laboratory Investigation. 
 Figure 3. (A) Pri-miR-133a-2 multiple species sequence alignment. Pre-miR-133a-2 is indicated in a blue box, mature MiR-133A is indicated 
in a red box, the seed region is highlighted, rs13040413 and rs200375711 are indicated by black arrows. (B) Pre-miR-133a-2 secondary 
structure, mature MiR-133A is indicated in red, n.98C is indicated in blue. Secondary structure was predicted using RNAfold Web Server 
[50]. This Figure is reproduced in colour in the online version of The Scandinavian Journal of Clinical & Laboratory Investigation. 
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human inherited condition associated with miRNA 
mutations; when they discovered that mutations in 
the seed region of MiR-96 were responsible for non-
syndromic progressive hearing loss in two families 
[57]. Outside of the seed region several variants have 
been associated with clinical phenotypes. Dorn et  al. 
demonstrated that a rare variant in mature MiR-499 
protected against cardiomyopathy in a transgenic 
mouse model [58] and Ohanian et  al. identifi ed a 
genetic variant in  mir-133a-2 which altered strand 
abundance resulting in an accumulation of the 
miRNA * strand in an atrial fi brillation patient [59]. 
Furthermore, several SNPs in pri-miRNA genes 
have been reported to affect processing and expres-
sion levels of mature miRNA [52]. 
 Conclusion 
 To the best of our knowledge, this is the fi rst study 
to report miRNA genetic variation in LQTS patients. 
We found three allelic variations none of which affect 
the mature miRNA products, although the  miR-
133a-2:n.98C  T variant is present in the excised 
pre-miRNA molecule (Figure 1) and may affect sub-
sequent processing to mature MiR133A. Our fi nd-
ings indicate that sequence variation of  miR1-1 , 
 miR1-2 ,  miR133a-1 and  miR133a-2 are not a cause 
of LQTS in this cohort. 
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